APA (7th ed.) Citation

SS, S., Y, Z., J, H., H, W., Y, L., D, D., . . . YG, N. (2022). Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma. Frontiers in oncology, 12, 1022496. https://doi.org/10.3389/fonc.2022.1022496

Chicago Style (17th ed.) Citation

SS, Shaikh, Zang Y, Hanmer J, Wang H, Lin Y, Davar D, Zarour HM, Kirkwood JM, and Najjar YG. "Phase I Trial of Pembrolizumab Plus Vemurafenib and Cobimetinib in Patients with Metastatic Melanoma." Frontiers in Oncology 12 (2022): 1022496. https://doi.org/10.3389/fonc.2022.1022496.

MLA (9th ed.) Citation

SS, Shaikh, et al. "Phase I Trial of Pembrolizumab Plus Vemurafenib and Cobimetinib in Patients with Metastatic Melanoma." Frontiers in Oncology, vol. 12, 2022, p. 1022496, https://doi.org/10.3389/fonc.2022.1022496.